Pert 2 in 1
- Manufacturer
- Sodalis USA, LLC
- Effective date
- 2025-07-30
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 2
- Source
- full-release
- Hydrated at
- 2026-06-01 01:09:25
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
OTC - ACTIVE INGREDIENT SECTION
Active ingredient
Salicylic Acid 3%
OTC - PURPOSE SECTION
Purpose
Antidandruff
INDICATIONS & USAGE SECTION
Use Controls the symptoms of dandruff
WARNINGS SECTION
Warnings
For external use only
OTC - WHEN USING SECTION
When using this product
- avoid contact with eyes. If contact occurs, rinse eyes thoroughly with water.
OTC - STOP USE SECTION
Stop use and ask a doctor if
- condition worsens or does not improve after regular use of this product as directed.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
DOSAGE & ADMINISTRATION SECTION
Directions
- For best results, use at least twice a week or as directed by a doctor.
- Shake before use.
- Gently massage into wet hair and scalp, lather and rinse. Repeat if desired.
INACTIVE INGREDIENT SECTION
Inactive ingredients: Water (aqua), sodium laureth sulfate, sodium lauryl sulfate, cocamidopropyl betaine, glycerin, cocamide MEA, dimethicone, glycol distearate, fragrance (parfum), guar hydroxypropyltrimonium chloride, sodium citrate, acrylates/C10-30 alkyl acrylate crosspolymer, sodium benzoate, sodium chloride, methylchloroisothiazolinone, methylisothiazolinone, sodium hydroxide, D&C Yellow no. 10, FD&C Blue no. 1
OTC - QUESTIONS SECTION
Questions or Comments?
1-800-575-7960
www.pert.com
SPL UNCLASSIFIED SECTION
Distributed by: Sodalis USA, LLC.
Westport, CT 06880
pert.com • 1-800-575-7960
Pert is a registeed trademark of Sodalis USA, LLC.
Made in Canada.
400248BL2
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
PERT®
EXTRA STRENGTH*
ANTI-DANDRUFF
2 IN 1
With
3% Salicylic Acid
QUAD ACTION FORMULA
- Cleans
- Conditions
- Reduces Flakes
- Fights Odors
SHAMPOO+CONDITIONER
12 FL OZ (355 mL)
DailyMed RxNorm Mappings#
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| c6f86816-7da6-43ea-8c25-ac9758311cc5 | Product name | 1 | 20220118 |
| dea2eded-d1e7-46bb-9a3d-f8dc20de6277 | Product name | 1 | 20190408 |
| 252e11b6-1a9a-4283-a242-df2c129c496d | Product name | 3 | 20170717 |
| d5e51f11-ad28-caa4-4b49-4143974782ad | Product name | 1 | 20150831 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 81277-803-12 | Pert 2 in 1Extra Strength | 355 mL in 1 BOTTLE | SHAMPOO | 355 | 2 |
Products#
Every source-derived product name is available through these pages.
- Pert 2 in 1 Extra Strength
- Salicylic Acid
- GUAR HYDROXYPROPYLTRIMONIUM CHLORIDE (1.7 SUBSTITUENTS PER SACCHARIDE)
- ACRYLATES/C10-30 ALKYL ACRYLATE CROSSPOLYMER (60000 MPA.S)
- GLYCERIN
- COCO MONOETHANOLAMIDE
- GLYCOL DISTEARATE
- SODIUM CITRATE
- WATER
- DIMETHICONE
- SODIUM BENZOATE
- SODIUM CHLORIDE
- D&C YELLOW NO. 10
- COCAMIDOPROPYL BETAINE
- FD&C BLUE NO. 1
- SODIUM LAURETH SULFATE
- METHYLISOTHIAZOLINONE
- SODIUM LAURYL SULFATE
- METHYLCHLOROISOTHIAZOLINONE
- SODIUM HYDROXIDE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 81277-803 | 81277-803-12 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Pert 2 in 1 Extra Strength | SALICYLIC ACID | Sodalis USA, LLC | 25c8a46c-4400-709f-e063-6394a90a3f31 | 2025-07-30 | Warnings | 81277-803-12 81277-803 81277080312 3ba3f0a1-4214-b7c6-e063-6294a90adbb4 25c8a46c-4400-709f-e063-6394a90a3f31 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.

